Merck’s Isentress – Is $27/Day A High Price To Pay For HIV Treatment?
Executive Summary
Merck's first-in-class integrase inhibitor Isentress marks the firm's return to the HIV market, but also to the intense pricing scrutiny that surrounds AIDS products